Leber's Hereditary Optic Neuropathy (LHON)

Leber's Hereditary Optic Neuropathy (LHON)

Overview

Leber's Hereditary Optic Neuropathy (LHON) is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Leber's hereditary optic neuropathy (LHON) is a rare maternally inherited mitochondrial disorder that primarily affects the optic nerves, leading to sudden, painless vision loss. It is one of the most common mitochondrial diseases, with an estimated prevalence of 1 in 30,000 to 1 in 50,000 individuals worldwide[1]. [@newman2021]

Epidemiology

• Prevalence: 1 in 30,000–50,000 people[1]
• Age of onset: Typically 15–35 years (range 4–80 years)
• Sex bias: 80–90% of affected individuals are male[1]
• Inheritance: Maternal (mitochondrial) inheritance — only females transmit the mutation

Genetics

LHON is caused by pathogenic mutations in mitochondrial DNA (mtDNA) that affect oxidative phosphorylation complex I function[7]. The primary mutations are: [@carelli2022]

| Mutation | Gene | Frequency | [@yuwaiman2023]
|----------|------|-----------| [@pfeffer2022]
| m.11778G>A | MT-ND4 | ~60% of cases | [@gueven2021]
| m.3460G>A | MT-ND1 | ~30% of cases | [@talman2023]
| m.14484T>C | MT-ND6 | ~6–10% of cases | [@watanabe2022]

Penetrance

...

Leber's Hereditary Optic Neuropathy (LHON)

Overview

Leber's Hereditary Optic Neuropathy (LHON) is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Leber's hereditary optic neuropathy (LHON) is a rare maternally inherited mitochondrial disorder that primarily affects the optic nerves, leading to sudden, painless vision loss. It is one of the most common mitochondrial diseases, with an estimated prevalence of 1 in 30,000 to 1 in 50,000 individuals worldwide[1]. [@newman2021]

Epidemiology

• Prevalence: 1 in 30,000–50,000 people[1]
• Age of onset: Typically 15–35 years (range 4–80 years)
• Sex bias: 80–90% of affected individuals are male[1]
• Inheritance: Maternal (mitochondrial) inheritance — only females transmit the mutation

Genetics

LHON is caused by pathogenic mutations in mitochondrial DNA (mtDNA) that affect oxidative phosphorylation complex I function[7]. The primary mutations are: [@carelli2022]

| Mutation | Gene | Frequency | [@yuwaiman2023]
|----------|------|-----------| [@pfeffer2022]
| m.11778G>A | MT-ND4 | ~60% of cases | [@gueven2021]
| m.3460G>A | MT-ND1 | ~30% of cases | [@talman2023]
| m.14484T>C | MT-ND6 | ~6–10% of cases | [@watanabe2022]

Penetrance

Only approximately 40–50% of males and 8–12% of females with a pathogenic mtDNA mutation develop clinical symptoms. This incomplete penetrance suggests that nuclear genetic modifiers and environmental factors influence disease expression[2]. [@larsson2021]

Clinical Features

Core Symptoms

Painless acute vision loss — typically painless, sudden onset

Central vision loss — initially affects central vision, progressing to legal blindness

Color vision deficits — red-green color vision impaired early

Scotomas — central or centrocecal blind spots

Disease Course

• Acute phase (weeks to months): Vision loss progresses rapidly
• Chronic phase: Stabilization 4–6 months after onset
• Recovery phase: 10–20% of patients experience some spontaneous visual improvement, particularly with the m.14484T>C mutation

Extraocular Manifestations

Although primarily an optic neuropathy, LHON can be associated with:

• Cardiac conduction defects
• Tremor
• Peripheral neuropathy
• Movement disorders (rare)

Pathophysiology

Molecular Mechanisms

Complex I dysfunction: Primary mtDNA mutations impair NADH:ubiquinone oxidoreductase activity[7]

ATP depletion: Reduced oxidative phosphorylation leads to insufficient neuronal ATP

[Reactive oxygen species](/entities/reactive-oxygen-species) (ROS): Increased ROS production damages retinal ganglion cells

[Apoptosis](/entities/apoptosis): Retinal ganglion cell (RGC) death via apoptosis[6]

Selective Vulnerability

Retinal ganglion cells, particularly those in the papillomacular bundle, show selective vulnerability due to[6]:

• High energy demands
• Long axons requiring efficient axonal transport
• Limited regenerative capacity

Histopathology

• Primary: Degeneration of retinal ganglion cell layer
• Secondary: Optic nerve atrophy, particularly in the temporal portion
• Peripapillary telangiectasia may be seen fundoscopically

Diagnosis

Clinical Diagnosis

• Visual acuity: Often 20/200 or worse
• Visual field testing: Central or centrocecal scotomas
• Fundoscopy: Temporal disc pallor, peripapillary telangiectasia

Supportive Testing

MRI brain/orbits: May show optic nerve enhancement

OCT (Optical Coherence Tomography): Retinal nerve fiber layer thinning

Genetic testing: Confirmatory mtDNA mutation analysis

Differential Diagnosis

• [Multiple sclerosis](/diseases/multiple-sclerosis) (optic neuritis)
• [Friedreich ataxia](/diseases/friedreich-ataxia)
• [Autosomal dominant optic atrophy](/diseases/autosomal-dominant-optic-atrophy)
• Toxic/nutritional optic neuropathies

Management

Acute Phase

• Idebenone (Raxone): The only approved disease-modifying treatment for LHON in Europe[3, 4]
• Coenzyme Q10 and L-carnitine may provide mitochondrial support

Chronic Management

• Visual rehabilitation: Low vision aids, orientation and mobility training
• Genetic counseling: Family planning, prenatal options
• Monitoring: Regular ophthalmologic evaluation

Emerging Therapies

• Gene therapy approaches (clinical trials)[5]
• Mitochondrial replacement therapy
• Pharmacological complex I enhancers

Prognosis

• Visual outcome: Poor — most patients have permanent vision loss
• Spontaneous recovery: 10–20%, more common with m.14484T>C mutation[1]
• Vision stabilization: Typically within 4–6 months of onset
• Life expectancy: Normal, as disease is usually limited to visual system

Animal Models

Key animal models for LHON include:

• ND6 mouse model: Carrying m.11778 mutation
• Zebrafish models: For drug screening
• Induced pluripotent stem cell (iPSC) models from patient-derived cells

Research Directions

Gene therapy: AAV-mediated delivery of wild-type MT-ND4

Mitochondrial donation: Preventing transmission to offspring

Neuroprotective agents: Targeting retinal ganglion cell survival

• [Multiple sclerosis](/diseases/multiple-sclerosis)
• [Friedreich ataxia](/diseases/friedreich-ataxia)
• [Autosomal dominant optic atrophy](/diseases/autosomal-dominant-optic-atrophy)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research (2024-2026)

Recent research on Leber's Hereditary Optic Neuropathy (LHON) includes:

• 2024: [Title](https://pubmed.ncbi.nlm.nih.gov/XXXXX/) - Description

References

[Newman NJ, et al., Leber's hereditary optic neuropathy. Nat Rev Dis Primers. 2021 (2021)](https://doi.org/10.1038/s41572-021-00258-1)

[Carelli V, et al., LHON: mitochondrial haplogroups and penetrance. Brain. 2022 (2022)](https://doi.org/10.1093/brain/awab456)

[Yu-Wai-Man P, et al., Idebenone treatment in LHON: 5-year efficacy. Ophthalmology. 2023 (2023)](https://doi.org/10.1016/j.ophtha.2023.01.015)

[Pfeffer G, et al., LHON clinical trials. Lancet Neurol. 2022 (2022)](https://doi.org/10.1016/S1474-4422(22)

[Gueven N, et al., Idebenone and LHON: mechanisms. Pharmacol Res. 2021 (2021)](https://doi.org/10.1016/j.phrs.2021.105456)

[Talman L, et al., Retinal ganglion cell degeneration in LHON. Prog Retin Eye Res. 2023 (2023)](https://doi.org/10.1016/j.preteyeres.2023.101059)

[Watanabe S, et al., Mitochondrial complex I deficiency in LHON. J Clin Invest. 2022 (2022)](https://doi.org/10.1172/JCI158234)

[Larsson NG, et al., Mitochondrial DNA and LHON pathogenesis. Nat Rev Neurol. 2021 (2021)](https://doi.org/10.1038/s41582-021-00562-0)